Erik S. G

Dec 6, 2024 | academic.oup.com | Amsterdam UMC |Erik S. G |Vrije Universiteit Amsterdam |Cheyenne Y Y

Inflammation is an important driver of disease in the context of atherosclerosis, and several landmark trials have shown that targeting inflammatory pathways can reduce cardiovascular event rates. However, the high cost and potentially serious adverse effects of anti-inflammatory therapies necessitate more precise patient selection.

Nov 19, 2024 | ejnmmires.springeropen.com | de Wit |Erik S. G |Amsterdam UMC |Ischemic Syndromes

This study had an open-label design to assess the safety, whole-body biodistribution kinetics, and dosimetry of 99mTc-fucoidan in 10 healthy volunteers consisting of 5 male and 5 female subjects. 99mTc-fucoidan was synthesized according to GMP guidelines as described previously [14] and produced by Eurofins Amatsi Group (Fontenilles, France). The molar activity of 99mTc-fucoidan was 2994 ± 872 MBq/nmol at the end of synthesis, and the radiochemical purity exceeded 95% in every batch.

Oct 30, 2024 | academic.oup.com | Amsterdam UMC |Erik S. G |G Kees

Accepted manuscripts are PDF versions of the author’s final manuscript, as accepted for publication by the journal but prior to copyediting or typesetting. They can be cited using the author(s), article title, journal title, year of online publication, and DOI. They will be replaced by the final typeset articles, which may therefore contain changes. The DOI will remain the same throughout.